Frazier Lifesciences Acquisition Corporation Share Price
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.41 EUR | +3.13% | +1.62% | +73.77% |
Sales 2024 * | 8.61M 9.32M 732M | Sales 2025 * | 6.3M 6.82M 536M | Capitalization | 1.54B 1.66B 131B |
---|---|---|---|---|---|
Net income 2024 * | -209M -226M -17.78B | Net income 2025 * | -139M -151M -11.83B | EV / Sales 2024 * | 178 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 244 x |
P/E ratio 2024 * |
-7.32
x | P/E ratio 2025 * |
-11.4
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
Latest transcript on Frazier Lifesciences Acquisition Corporation
1 day | +3.13% | ||
1 week | +1.62% | ||
Current month | -11.00% | ||
1 month | -11.00% | ||
3 months | -17.54% | ||
6 months | +98.87% | ||
Current year | +73.77% |
Date | Price | Change | Volume |
---|---|---|---|
30/05/24 | 18.5 | -2.50% | 91,047 |
29/05/24 | 18.98 | -2.22% | 103,242 |
28/05/24 | 19.41 | +3.13% | 236,777 |
24/05/24 | 18.82 | -1.47% | 131,706 |
23/05/24 | 19.1 | -2.45% | 35,045 |
End-of-day quote Nasdaq, May 27, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.77% | 1.71B | |
+8.92% | 114B | |
+10.48% | 104B | |
-1.83% | 22.57B | |
-6.45% | 22.5B | |
-10.39% | 17.95B | |
-42.36% | 16.48B | |
-14.45% | 15.82B | |
+3.76% | 13.55B | |
+28.94% | 10.99B |
- Stock Market
- Equities
- NAMS Stock